Nascent Biotech Inc.: Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical

Milestone Payment is the Second of Four in $5M Pritumumab Licensing DealVERO BEACH, FL / ACCESSWIRE / February 23, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company")

Related Keywords

United States ,America ,Kostenloser Wertpapierhandel ,Sean Carrick ,Exchange Commission ,Bioray Pharmaceutical Ltd ,Nascent Biotech Inc ,Securities Exchange ,Nascent Biotech Inc Form ,Milestone Payment ,Pritumumab Licensing ,Nascent Biotech ,Bioray Pharmaceutical ,Licensing Agreement ,Second Payment ,North America ,Securities Act ,Securities Exchange Act ,Private Litigation Reform Act ,Nascent ,Biotech ,Eceives ,650k ,Milestone ,Payment ,Rom ,Bioray ,Harmaceutical ,